According to reports, CD161 is an anti-tumor inhibitory receptor that T cells that infiltrate diffuse glioblastoma utilize to mediate the suppression of the CLCE2D-CD161 signaling pathway, which in turn enhances the anti-tumor immunological impact of diffuse glioma by working in concert with the anti-tumor immune response (Mathewson et al. 2021a, b). Here, KLRB1 is linked to neoplasm.